Category Archives: Myocardial Infarction

VANCOUVER, British Columbia, March 04, 2020 (GLOBE NEWSWIRE) -- PAI Health, a heart health software company, has been awarded the contract to develop the technology platform for the largest exercise intervention study ever performed. The study, called The Norwegian Trial of Physical Exercise after Myocardial Infarction (NorEx), will be undertaken at NTNU, the Norwegian University of Science and Technology. NorEx is a registry-based multicenter and multiregional randomized controlled trial for secondary prevention and rehabilitation of patients who have suffered myocardial infarction (MI). Continue reading →

Intensive glucose-lowering therapy was found to be associated with a reduced risk for incident coronary heart disease (CHD) and cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) and a haptoglobin (Hp) Hp2-2 genotype, but not in patients with an Hp1 genotype, according to a study published in the Journal of the American College of Cardiology. The study is a reanalysis of the Action to Control Cardiovascular Risk in Diabetes (ClinicalTrials.gov identifier: NCT00000620) double-blind 2 x 2 factorial trial, in which 5806 white adult participants from the United States and Canada (mean age, 63.16.3 years; 36% women; median T2D duration at baseline, 9 years) were enrolled Continue reading →

BACKGROUND AND OBJECTIVE: Our aims were to improve the understanding of the pathogenic relationship between cardiovascular diseases and periodontitis and to generate new perspectives in the prevention and treatment of acutemyocardial infarction(AMI) and periodontitis. The present study evaluates possible differences in inflammation, oxidative stress, and autophagy markers among subject suffering AMI, periodontitis, or both, to explore possible common pathogenic mechanisms. Continue reading →

OBJECTIVES: We aimed to study adoption of transradial primary percutaneous coronary intervention (TR-PPCI) for ST elevationmyocardial infarction(STEMI) (radial first approach) and its association with door-to-balloon time (D2BT). TR-PPCI for STEMI is underutilized in the United States due to concerns about prolonging D2BT Continue reading →

PUNE, India, March 4, 2020 /PRNewswire/ -- A recent report by Infinium Global Research's on the "Cardiac Biomarkers Market(Type - Myocardial Muscle Creatine Kinase (CK-MB), Troponins (T and I), Myoglobin, Brain Natriuretic Peptide (BNPs) or NT-proBNP, Ischemia Modified Albumin (IMA), and Other Types; Location of Testing - Point of Care Testing, and Laboratory Testing; Applications - Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Other Applications): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025"estimates that the market is projected to expand with a CAGR of 12.5% over the period of 2019 to 2025 and would be worth USD 14 Billion by 2025. Continue reading →

JSC Grindeks announces that it has completed the Phase 1 clinical study of its new investigational medicinal product metyl-GBB. This new investigational medicinal product is intended for the treatment of cardiovascular diseases. This treatment will have a unique therapeutic advantage the new medicine will be available in both parenteral and oral dosage forms. Continue reading →

In the early rule-out of myocardial infarction, outcomes may be improved by accounting for the patients out-of-hospital experience, improving reassurance communication, and discussing future goals for cardiovascular health, according to a study published in Annals of Emergency Medicine. Continue reading →

1. Continue reading →

The US Food and Drug Administration (FDA) has additionally approved dulaglutide (Trulicity, Lilly) for reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes with and without established cardiovascular disease (CVD) or multiple CV risk factors, the company has announced. Continue reading →

Data from BIOFLOW-V Trial Presented at CRT and Published in JACC: Cardiovascular Interventions Reinforces Orsiro's Ability to Outperform Abbott's Xience NATIONAL HARBOR, Md., Feb. Continue reading →